BioInvent International
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy. The company is advancing its clinical programs with a strategic focus on its lead assets, BI-1206 and BI-1808, which show promise in treating liquid and solid cancers. BioInvent collaborates with pharmaceutical companies and academic institutions to enhance its research capabilities and expand its clinical pipeline. The company is headquartered in Sweden and operates globally, leveraging partnerships to drive innovation and value creation in oncology treatments.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes BI-1206 and BI-1808 for cancer treatment
Includes BT-001 developed with Transgene
Projects licensed to other companies for development
Production of antibodies for clinical studies
Customers
BioInvent's customer base includes pharmaceutical companies and academic institutions engaged in oncology research and development. The company collaborates with leading pharmaceutical firms such as Takeda and AstraZeneca to advance its clinical assets. Academic partnerships allow BioInvent to access cutting-edge scientific expertise and potentially acquire new assets for development. The company's outlicensed projects provide opportunities for milestone payments and royalties, appealing to partners seeking innovative cancer therapies.
Buy novel cancer therapies and collaborate on clinical assets
Collaborate on research and provide scientific expertise
Engage in projects with potential for milestone payments
Strategy
BioInvent's strategic focus is on accelerating the development of its lead clinical programs, BI-1206 and BI-1808, to maximize therapeutic impact and shareholder value. The company has paused less promising projects to concentrate resources on these assets, which have shown strong clinical signals. BioInvent aims to enhance value creation through strategic collaborations and partnerships. The company's disciplined approach is designed to support future growth while maintaining core research capabilities.
To maximize therapeutic impact and shareholder value
To enhance value creation and expand clinical pipeline
Geography
Q3/2025BioInvent is headquartered in Sweden and operates globally, with significant collaborations in Europe and the USA. The company's strategic partnerships with pharmaceutical giants like AstraZeneca and Takeda extend its reach in key markets. BioInvent's antibody production facilities are located in Sweden, supporting its clinical studies worldwide. The company's geographic presence is crucial for accessing diverse markets and leveraging international expertise in oncology research.
Share of the revenue the company reports by geography.
Risks
BioInvent faces several risks, including the inherent uncertainties of clinical trials and regulatory approvals. The company's reliance on strategic partnerships exposes it to risks related to partner performance and collaboration outcomes. Financial risks include potential fluctuations in revenue from outlicensed projects and antibody production. Industry-specific risks such as changes in healthcare regulations and competitive pressures also pose challenges. BioInvent must navigate these risks to achieve its strategic objectives and maintain its competitive position.
- Clinical Trial UncertaintyImpact: CriticalLikelihood: Medium
Potential delays or failures in trials
- Partnership DependencyImpact: HighLikelihood: Medium
Reliance on partner performance for project success
- Revenue FluctuationImpact: MediumLikelihood: Medium
Variability in income from outlicensed projects
Accounting
Judgemental itemsAffects variability in reported income
Impact: medium
Influence financial performance and cash flow
Impact: high
Similar listed companies
Publicly listed companies with a comparable business focus.
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
BioVie Inc
BIVIW · Pharmaceutical Preparations
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
ArriVent BioPharma, Inc.
AVBP · Pharmaceutical Preparations
Inventiva S.A.
IVA · Pharmaceutical Preparations
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Last updated: 24/09/2026